The New York Times reports that internal marketing documents show that “Eli Lilly encouraged primary care physicians to use Zyprexa, in patients who did not have either condition.”
THE NEW YORK TIMES EXPOSE OF ELI LILLY SECRET ZYPREXA DOCUMENTS Part II.
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
Two ground breaking legal actions in Texas to rein in out of control psychotropic drug prescribing will have nationwide reverberations.
BBC reports that "Up to one in three mental health patients are being over-prescribed drugs, says the Healthcare Commission."
Unssuccessful effort to engage debate within the community of the authorized clinical research gatekeepers charged with protecting the safety and welfare of the human subjects of research–i.e., members of institutional review boards (IRBs–REBs in Canada).
A video you MUST SEE–an ex-Zyprexa sales rep spills the beans!
U.S. State Attorneys General should investigate the fraudulent marketing of the atypical neuroleptic drugs-and FDA's role in helping conceal the truth.
The Baltimore Sun reports (below) that in a paper scheduled for publication in the journal Epidemiology and Infection, a Harvard University-led team proposes that a vitamin D deficiency caused by inadequate winter sun exposure may predispose people to infection.
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
Dr. E. Jane Costello, a professor of psychiatry and behavioral sciences at Duke University, acknowledges: “The system of diagnosis is still 200 to 300 years behind other branches of medicine.” Psychiatry also fails to be guided by an evidence-based positive benefit / risk assessment of its prescribed treatments.
